<![CDATA[  Regimen Bleomisin Oncovin® Mitomisin-Karboplatin (BOM-Karboplatin) sebagai kemoterapi tidak terlepas dari efek samping yang ditimbulkan yaitu toksisitas pada organ tubuh diantaranya adalah ginjal, hati, dan darah, dimana terjadinya toksikitas pada organ ginjal dapat diindikatorkan dengan parameter Serum Kreatinin dan Blood Urea Nitrogen (BUN). Terjadinya toksisitas pada organ hati dapat diukur dengan parameter SGOT dan SGPT serta toksisitas pada fungsi darah diindikatorkan dengan nilai hemoglobin, trombosit, leukosit. Belum terdapat data mengenai efek toksik dari kemoterapi BOM-Karboplatin pada pasien kanker serviks sel skuamosa stadium IIBâIIIB di RSUP Sanglah Denpasar, sehingga penelitian ini dilakukan melalui pemantauan terhadap fungsi ginjal, hati dan darah. Penelitian ini merupakan studi kasus observasional terhadap sembilan pasien yang diikuti selama tiga seri kemoterapi dari bulan Februari hingga Agustus 2015. Data serum kreatinin, BUN, SGOT, SGPT, hemoglobin, trombosit, dan leukosit yang diperoleh dianalisis menggunakan uji t berpasangan untuk data yang terdistribusi normal dan uji Wilcoxon untuk data yang tidak terdistribusi normal dengan tingkat kepercayaan 95% dan dikatakan berbeda bermakna bila p<0,05. Hasil studi kasus ini menunjukkan nilai serum kreatinin (p=0,530), BUN (p=0,553), SGOT (p=0,162), SGPT (p=0,054), Hemoglobin (p=0,034), Trombosit (p=0,028), dan Leukosit (p=0,011), sehingga dapat disimpulkan bahwa terdapat penurunan fungsi darah yang signifikan ditandai dengan adanya penurunan signifikan pada parameter hemoglobin, trombosit dan leukosit sebelum kemoterapi I dan sesudah kemoterapi III BOM-Karboplatin, sehingga diperlukan monitoring ketat terhadap fungsi darah pasien yang menerima kemoterapi BOM-Karboplatin di RSUP Sanglah Denpasar.Kata kunci: BOM-Karboplatin, fungsi darah, kanker serviks, kemoterapi, RSUP Sanglah, toksisitasThe Difference of Kidney, Heart and Blood Function on Cervical Cancer Patients with Chemotherapy, Bleomycin, Oncovin®, Mitomycin and Carboplatin (Case Study in Sanglah General Hospital, Denpasar in 2015) Oncovin® bleomycin mitomycin-carboplatin (BOM-carboplatin) regimen as chemotherapy is inseparable from the side effects it can caused which is toxicity to organs including the kidneys, liver, and blood where the toxicity in the kidneys can be indicated by the parameter of Serum Creatinine and Blood Urea Nitrogen (BUN), the occurrence of toxicity in the liver can be measured by the parameters of SGOT and SGPT, and toxicity to blood function can be indicated by the value of hemoglobin, platelets, leukocytes. The absence of data on the toxic effects of chemotherapy BOM-carboplatin in patients with squamous cell cervical cancer stage IIBâIIIB in Sanglah General Hospital in Denpasar, had made this research conducted through monitoring of kidney, liver and blood function. This study is an observational case study of nine patients who were followed for three rounds of chemotherapy from February to August 2015. Data of creatinine serum, BUN, SGOT, SGPT, hemoglobin, platelets, and leukocytes were analyzed using paired t-test for the data that were normally distributed and Wilcoxon test for the data that were not normally distributed with a confidence level of 95% and was said to be significantly different when p<0.05. The results of this case study demonstrated the value of serum creatinine (p=0.530), BUN (p=0.553), SGOT (p=0.162), SGPT (p=0.054), hemoglobin (p=0.034), platelets (p=0.028), and leukocytes (p=0.011) so it could be concluded that there was a significant decrease of blood function which could be characterized by a significant decrease in the parameters of hemoglobin, platelets and leucocytes before chemotherapy I and after chemotherapy III BOM-carboplatin, so it required strict monitoring of the blood function of the patients who received chemotherapy BOM-carboplatin in Sanglah General Hospital in Denpasar.Keywords: BOM-carboplatin, blood function, cervical cancer, chemotherapy, Sanglah General Hospital, toxicity]]>
Copyrights © 2016
